Recently, treatment of acute episodes of TTP with increasing use of rituximab and the addition of new agents, such as caplacizumab [16] and recombinant ADAMTS13 showed to be more effective. Here, ADAMTS13 is linked to thrombotic thrombocytopenic purpura.